COMPARISON OF INDIVIDUAL PHARMACOKINETIC DOSING TOOLS IN PATIENTS WITH HEMOPHILIA A

Objective: Prophylaxis treatment is recommended for the prevention of bleeding and complications in patients with hemophilia A. Personalized treatment methods are an up-to-date approach. Hemophilia treatment is suitable for optimization with pharmacokinetic (PK) methods. It has been shown that proph...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Can Alp GENÇ, Dilek GURLEK GOKCEBAY, Vildan KOSAN CULHA, Namık Yasar Ozbek, Yasin KOKSAL, Zühre Kaya
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/f580bfce1c554d82ac5c0977b8438422
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f580bfce1c554d82ac5c0977b8438422
record_format	dspace
spelling	oai:doaj.org-article:f580bfce1c554d82ac5c0977b84384222021-11-10T04:33:05ZCOMPARISON OF INDIVIDUAL PHARMACOKINETIC DOSING TOOLS IN PATIENTS WITH HEMOPHILIA A2531-137910.1016/j.htct.2021.10.983https://doaj.org/article/f580bfce1c554d82ac5c0977b84384222021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921011305https://doaj.org/toc/2531-1379Objective: Prophylaxis treatment is recommended for the prevention of bleeding and complications in patients with hemophilia A. Personalized treatment methods are an up-to-date approach. Hemophilia treatment is suitable for optimization with pharmacokinetic (PK) methods. It has been shown that prophylaxis regulated with PK data reduces the frequency of bleeding and the cost of treatment. To determine the best prophylaxis regimen, PK dose tools using the Bayesian method have been developed. Methodology: Blood samples were obtained from 42 patients with severe hemophilia A (median age 13.4 years) with factor VIII (FVIII) inhibitor <0.6 BU/ml and no additional disease that would affect the FVIII level before the FVIII infusion, 4, 24 and 48 hours after the infusion. FVIII levels from blood samples were measured by PTT-based one-stage assay method. PK parameters obtained using WAPPS and myPKFIT programs, which are two web-accessed PK dosing tools using the Bayesian algorithm, were compared. Results: There was no significant difference between the daily dose of FVIII given in prophylaxis and the dose amount recommended by the myPKFIT program for the 1% trough, but a difference was found with the WAPPS program. While there was no significant difference between the half-lives (t1/2) and the time to 5% of plasma FVIII between the two PK tools, there were significant differences in the recommended dose amounts, clearance (CL), times up to 1% and 2% of plasma FVIII. Conclusion: As a result of cross-pair comparison between the treatment doses received by the patients and the doses recommended by the PK dosing tools, significant differences were found as well as similarities. Besides similar results, significant differences were also found among the PK parameters. Previous studies didn't compare CLs between myPKFIT and WAPPS, this is the first in our study. While no difference was found between t1/2’s, the difference between recommended doses may be due to CL difference.Can Alp GENÇDilek GURLEK GOKCEBAYVildan KOSAN CULHANamık Yasar OzbekYasin KOKSALZühre KayaElsevierarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S21-S22 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Can Alp GENÇ Dilek GURLEK GOKCEBAY Vildan KOSAN CULHA Namık Yasar Ozbek Yasin KOKSAL Zühre Kaya COMPARISON OF INDIVIDUAL PHARMACOKINETIC DOSING TOOLS IN PATIENTS WITH HEMOPHILIA A
description	Objective: Prophylaxis treatment is recommended for the prevention of bleeding and complications in patients with hemophilia A. Personalized treatment methods are an up-to-date approach. Hemophilia treatment is suitable for optimization with pharmacokinetic (PK) methods. It has been shown that prophylaxis regulated with PK data reduces the frequency of bleeding and the cost of treatment. To determine the best prophylaxis regimen, PK dose tools using the Bayesian method have been developed. Methodology: Blood samples were obtained from 42 patients with severe hemophilia A (median age 13.4 years) with factor VIII (FVIII) inhibitor <0.6 BU/ml and no additional disease that would affect the FVIII level before the FVIII infusion, 4, 24 and 48 hours after the infusion. FVIII levels from blood samples were measured by PTT-based one-stage assay method. PK parameters obtained using WAPPS and myPKFIT programs, which are two web-accessed PK dosing tools using the Bayesian algorithm, were compared. Results: There was no significant difference between the daily dose of FVIII given in prophylaxis and the dose amount recommended by the myPKFIT program for the 1% trough, but a difference was found with the WAPPS program. While there was no significant difference between the half-lives (t1/2) and the time to 5% of plasma FVIII between the two PK tools, there were significant differences in the recommended dose amounts, clearance (CL), times up to 1% and 2% of plasma FVIII. Conclusion: As a result of cross-pair comparison between the treatment doses received by the patients and the doses recommended by the PK dosing tools, significant differences were found as well as similarities. Besides similar results, significant differences were also found among the PK parameters. Previous studies didn't compare CLs between myPKFIT and WAPPS, this is the first in our study. While no difference was found between t1/2’s, the difference between recommended doses may be due to CL difference.
format	article
author	Can Alp GENÇ Dilek GURLEK GOKCEBAY Vildan KOSAN CULHA Namık Yasar Ozbek Yasin KOKSAL Zühre Kaya
author_facet	Can Alp GENÇ Dilek GURLEK GOKCEBAY Vildan KOSAN CULHA Namık Yasar Ozbek Yasin KOKSAL Zühre Kaya
author_sort	Can Alp GENÇ
title	COMPARISON OF INDIVIDUAL PHARMACOKINETIC DOSING TOOLS IN PATIENTS WITH HEMOPHILIA A
title_short	COMPARISON OF INDIVIDUAL PHARMACOKINETIC DOSING TOOLS IN PATIENTS WITH HEMOPHILIA A
title_full	COMPARISON OF INDIVIDUAL PHARMACOKINETIC DOSING TOOLS IN PATIENTS WITH HEMOPHILIA A
title_fullStr	COMPARISON OF INDIVIDUAL PHARMACOKINETIC DOSING TOOLS IN PATIENTS WITH HEMOPHILIA A
title_full_unstemmed	COMPARISON OF INDIVIDUAL PHARMACOKINETIC DOSING TOOLS IN PATIENTS WITH HEMOPHILIA A
title_sort	comparison of individual pharmacokinetic dosing tools in patients with hemophilia a
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/f580bfce1c554d82ac5c0977b8438422
work_keys_str_mv	AT canalpgenc comparisonofindividualpharmacokineticdosingtoolsinpatientswithhemophiliaa AT dilekgurlekgokcebay comparisonofindividualpharmacokineticdosingtoolsinpatientswithhemophiliaa AT vildankosanculha comparisonofindividualpharmacokineticdosingtoolsinpatientswithhemophiliaa AT namıkyasarozbek comparisonofindividualpharmacokineticdosingtoolsinpatientswithhemophiliaa AT yasinkoksal comparisonofindividualpharmacokineticdosingtoolsinpatientswithhemophiliaa AT zuhrekaya comparisonofindividualpharmacokineticdosingtoolsinpatientswithhemophiliaa
_version_	1718440710784417792

COMPARISON OF INDIVIDUAL PHARMACOKINETIC DOSING TOOLS IN PATIENTS WITH HEMOPHILIA A

Ejemplares similares